Lemaitre Vascular (LMAT) Cash & Equivalents (2010 - 2026)

Lemaitre Vascular (LMAT) has 17 years of Cash & Equivalents data on file, last reported at $26.9 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 5.96% year-over-year to $26.9 million in Q1 2026; TTM through Mar 2026 was $26.9 million, a 5.96% increase from a year earlier, with the FY2025 full-year figure at $28.2 million, up 10.29% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $26.9 million, down from $28.2 million in the prior quarter.
• Over the last five years, Cash & Equivalents for LMAT reached as high as $28.2 million in Q4 2025 and fell as low as $15.6 million in Q1 2022.
• Historically, Cash & Equivalents has averaged $22.3 million across 5 years, with a median of $22.3 million in 2024.
• Across the five-year window, Cash & Equivalents plunged 33.86% in 2022 and surged 59.47% in 2024, its largest moves.
• Year by year, Cash & Equivalents stood at $19.1 million in 2022, then climbed by 26.84% to $24.3 million in 2023, then gained by 5.53% to $25.6 million in 2024, then increased by 10.29% to $28.2 million in 2025, then dropped by 4.93% to $26.9 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $26.9 million in Q1 2026, $28.2 million in Q4 2025, and $25.5 million in Q3 2025.